RxDoctor Payments Data

Ngoc Duran

Family · Victoria, TXNPI 1487021762

Payments from drug & device makers

$2,366in general payments, 2019–2025

Across 134 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$604
  • AbbVie$424
  • Astellas Pharma US Inc$189
  • Takeda Pharmaceuticals U.S.A., Inc.$179
  • Amgen$129
  • Lilly USA, LLC$126
  • plus $717 from 13 others

What the payments were for

  • Food & beverage$2,27296%
  • Education$944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,366 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$48,691
Medicare patients
182
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$40,929
JanuviaSitagliptin Phosphate33$38,085
OzempicSemaglutide17$27,237
Soliqua 100-33Insulin Glargine/Lixisenatide17$23,179
MyrbetriqMirabegron20$21,036
FarxigaDapagliflozin Propanediol12$17,493
EliquisApixaban24$15,505
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,288
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,133
Albuterol Sulfate HfaAlbuterol Sulfate87$2,464
Levemir FlexpenInsulin Detemir13$2,253
Rosuvastatin Calcium141$1,332
Gabapentin74$1,196
Omeprazole71$1,134
Lisinopril128$1,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$604$27,23717 claims
AstraZenecaFarxiga, Breztri Aerosphere$97$23,78123 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$79$23,17917 claims
Astellas Pharma US IncMyrbetriq$189$21,03620 claims
PfizerEliquis$113$15,50524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →